Search Strategy Builder
Author, validate, and govern Boolean search strategies for literature surveillance.
Product Profile
Search-Term Sections
Editable tag lists grouped by term category.
Substance Synonyms
4 termsChemical entity and INN variants for the active substance.
Brand Names
3 termsMarketed trade names across all monitored regions.
Scientific Names
3 termsFull scientific / molecular descriptors.
Misspellings & Variants
4 termsCommon spelling variants captured from retrieval audit.
Combination / Co-administration Terms
3 termsConcomitant therapy combinations relevant to label.
Adverse Event Terms
6 termsMedDRA-aligned preferred terms of safety interest.
Special Situation Terms
6 termsPregnancy, paediatric, off-label, medication error, misuse.
Exclusion Terms
5 termsTerms to exclude from the Boolean query (noise reduction).
Search Strategy Copilot
Cardiomabumab is frequently discussed alongside the PCSK9 inhibitor class (alirocumab, evolocumab). Adding “PCSK9 inhibitor class” captures comparative-safety publications that name Cardiomab only by class.
The full enzyme name “proprotein convertase subtilisin/kexin type 9” appears in 41 indexed abstracts that do not use “PCSK9” or “cardiomabumab”.
Current query ANDs adverse-event terms, dropping articles where the AE appears only in the full text. Recommend: (cardiomabumab OR brand OR code) AND (ae1 OR ae2 …) within 5 words, OR abstract-anchored.
Excluding “healthy volunteer” removes Phase I safety reports that are in-scope per the RMP. Recommend narrowing to “healthy volunteer” NOT (“adverse” OR “reaction”).
Cardiomab is marketed in Japan but the strategy has no Japanese-language variants (心臓マブ, カルジオマブ). Embase JP and J-MEDLINE will under-return.
Accepting suggestions S1–S5 increases expected retrieval by ~62 articles/cycle (+15%). Estimated screening burden: +18 min human review / cycle.
Query Preview
[PubMed / MeSH]
("cardiomabumab" OR "anti-PCSK9 monoclonal antibody" OR "PCSK9i" OR "cardiomab" OR "Cardiomab" OR "Cardiomab prefilled pen" OR "CardioMab SC" OR "cardiomabumab acetate" OR "humanized IgG1 anti-PCSK9" OR "fully human monoclonal antibody PCSK9") AND ("myalgia" OR "rhabdomyolysis" OR "injection-site reaction" OR "hypersensitivity" OR "neurocognitive impairment" OR "hepatic enzyme increased") OR ("pregnancy exposure" OR "paediatric use" OR "off-label use" OR "medication error" OR "drug misuse" OR "lack of efficacy") OR (cardiomabumab AND statin OR cardiomabumab AND ezetimibe OR cardiomabumab AND PCSK9 inhibitor combination) NOT ("animal model" OR "in vitro" OR "preclinical" OR "healthy volunteer" OR "pharmacokinetics only")https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed&retmode=json&term=(cardiomabumab[TIAB]+OR+anti-PCSK9%20monoclonal%20antibody[TIAB]+OR+PCSK9i[TIAB]+OR+cardiomab[TIAB]+OR+Cardiomab[TIAB]+OR+Cardiomab%20prefilled%20pen[TIAB]+OR+CardioMab%20SC[TIAB]+OR+cardiomabumab%20acetate[TIAB]+OR+humanized%20IgG1%20anti-PCSK9[TIAB]+OR+fully%20human%20monoclonal%20antibody%20PCSK9[TIAB])+AND+(myalgia[TIAB]+OR+rhabdomyolysis[TIAB]+OR+injection-site%20reaction[TIAB]+OR+hypersensitivity[TIAB]+OR+neurocognitive%20impairment[TIAB]+OR+hepatic%20enzyme%20increased[TIAB])+NOT+(animal%20model[TIAB]+OR+in%20vitro[TIAB]+OR+preclinical[TIAB]+OR+healthy%20volunteer[TIAB]+OR+pharmacokinetics%20only[TIAB])&retmax=200&sort=date
Approval Workflow & Version Control
Controlled lifecycle: Draft → Under Review → Approved → Superseded. All transitions are auditable.
Version History
| Version | State | Author | Reviewer | Effective | Terms | Est. Vol |
|---|---|---|---|---|---|---|
| v3.0 | Approved | Dr. Elena Vasquez | Dr. Sven Eriksson | 2026-06-01 | 38 | 412 |
| v2.1 | Superseded | Dr. Marcus Lindqvist | Dr. Elena Vasquez | 2026-02-15 | 31 | 367 |
| v2.0 | Superseded | Dr. Elena Vasquez | Dr. Sven Eriksson | 2025-11-01 | 28 | 351 |
| v3.1 (draft) | Draft | Dr. Elena Vasquez | — | — | 34 | 412 |
Added special-situation term set; expanded AE terms with neurocognitive and hepatic PTs per RMP v2.3 update.